Anti-GSR polyclonal antibody

Conductive polymer composites can detect strain and pressure when subjected to large deformations. However, the complex strain sensing behaviors of the composites, such as the non-monotonic resistance response during cyclic loading, limit their further application. In this paper, the strain sensing behaviors have been optimally regulated through the synergistic effect and self-assembly of carbon nanotubes (CNTs) and graphene (GR) in silicone rubber (VMQ) composites. We found that the self-assembled CNTs-GR/VMQ composites have an incredibly low percolation threshold of 0.92 wt%, which is 53% lower than that of the CNTs/VMQ composites. Additionally, the resistance response of CNTs/VMQ and CNTs-GR/VMQ composites showed a significant downward drift and shoulder peak phenomenon, whereas the self-assembled CNTs-GR/VMQ composites exhibited a monotonic and more stable resistance response. Based on the morphology results of transmission electron microscopy and theoretical analysis, the uniform distribution of nanoparticles and the bridging structure formed by CNTs and GR are considered as the main reasons for the lower percolation threshold and the better resistance response.

CB-03-10 (cortexolone 17 alpha-valerate-21-propionate) is a synthetic steroidal compound derived from cortexolone (11-deoxycortisone), an intermediate in cortisol biosynthesis. Characterization of the activity of CB-03-10 and its main related compound CB-03-05 (cortexolone 17 alpha-valerate) included in vitro binding to the androgen and glucocorticoid receptors (AR and GR), antagonism of AR and GR transcriptional activities, and screening for antitumor activity across a selected panel of human prostate and in triple-negative breast cancer cell lines. CB-03-10 cytotoxic activity in these cancer cell lines was in the low micromolar range and was primarily associated with induction of the apoptotic cascade via activation of caspases. The compound's potential for antitumor activity was verified in a murine xenograft model utilizing the AR-positive LNCaP prostate cancer cell line as well as in an orthotopic model utilizing AR-negative/GR-positive MDA-MB-231 breast cancer cell line. Orally administered CB-03-10 inhibited prostate tumor growth and orthotopically implanted breast tumor growth in these mice and maintained body weight, as compared with vehicle-treated mice. On the basis of AR/GR binding affinities, antagonism of androgen and glucocorticoid-dependent transcriptional activities, and AR/GR mRNA and protein expression, the mechanism of tumor growth suppression is related to AR and GR antagonist activities. Importantly, these compounds lack biologically relevant AR/GR agonist activities. Overall, these preclinical findings support the selection of CB-03-10 for further development as an anticancer agent in cases where resistance to AR-targeted therapy or chemotherapy, via upregulation of GR activity, continues to limit the efficacy and duration of clinical benefit with these interventions.